Biotech | November 20, 2021
Oravax and Genomma JV to commercialise Covid-19 vaccine in Mexico and Latam
Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical
Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical
The final data from the trial showed sotrovimab reduces hospitalisation and risk of death by 79% in adults with mild-to-moderate Covid-19 who are at high risk of progression to severe disease
Six-months follow-up of prevention trial showed 83% reduced risk of symptomatic Covid-19, with no severe disease or deaths
It is anticipated to be safe and efficacious by targeting the receptor-binding domain (RBD) of the new coronavirus
If approved or authorized, Paxlovid would be the first oral antiviral of its kind, to combat SARS-CoV-2
The octocopter has successfully delivered 50 vials of Covid-19 vaccines along with syringes in a special container from Chandapura PHC to Haragadde PHC
The European Commission (EC) granted marketing authorisation for Celltrion’s regdanvimab following a positive opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) last week
Data demonstrates Ronapreve reduced risk of hospitalisation in certain patients and reduced risk of symptomatic Covid-19 infections in people exposed to the virus
A final decision regarding the approval of Ronapreve is expected from the European Commission shortly
Evidence also shows better immune response to virus among users of spray
Subscribe To Our Newsletter & Stay Updated
